Epoetin-alfa induced pruritic maculopapular eruption: Case report and literature review.

IF 1.9 4区医学 Q3 ALLERGY Asian Pacific journal of allergy and immunology Pub Date : 2023-09-01 DOI:10.12932/AP-040719-0592

Rawi Rueangsri, Wannada Laisuan

{"title":"Epoetin-alfa induced pruritic maculopapular eruption: Case report and literature review.","authors":"Rawi Rueangsri, Wannada Laisuan","doi":"10.12932/AP-040719-0592","DOIUrl":null,"url":null,"abstract":"Background: Erythropoiesis-stimulating agents (ESA) are commonly used in clinical practice to improve anaemia. Despite a number of patients successfully treated without adverse events, the complications have been previously reported.Objective: To report and review the characteristics and management of ESA hypersensitivities.Methods: Case reports and related articles associated with ESA use, published between January 1999 and December 2018, were retrieved through Electronic databases (MEDLINE® and PubMed®).Results: Forty-seven ESA patients with various immediate and delayed hypersensitivity reactions caused by epoetin and pharmaceutical excipients were identified from nineteen studies and one case report in this paper. Fatal hypersensitivity to ESA and ESA-allergic cross-reactivities have been documented. Desensitization or change of EPO molecular structure has been reported as successful methods of re-introducing the drug.Conclusions: ESA hypersensitivity in the various allergic reactions and cross-reactivity have been documented. Desensitization and Epoetin structural changes could be successful methods to re-introduce the drug.","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"231-235"},"PeriodicalIF":1.9000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific journal of allergy and immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12932/AP-040719-0592","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 1

Abstract

Background: Erythropoiesis-stimulating agents (ESA) are commonly used in clinical practice to improve anaemia. Despite a number of patients successfully treated without adverse events, the complications have been previously reported.

Objective: To report and review the characteristics and management of ESA hypersensitivities.

Methods: Case reports and related articles associated with ESA use, published between January 1999 and December 2018, were retrieved through Electronic databases (MEDLINE® and PubMed®).

Results: Forty-seven ESA patients with various immediate and delayed hypersensitivity reactions caused by epoetin and pharmaceutical excipients were identified from nineteen studies and one case report in this paper. Fatal hypersensitivity to ESA and ESA-allergic cross-reactivities have been documented. Desensitization or change of EPO molecular structure has been reported as successful methods of re-introducing the drug.

Conclusions: ESA hypersensitivity in the various allergic reactions and cross-reactivity have been documented. Desensitization and Epoetin structural changes could be successful methods to re-introduce the drug.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Epoetin-alfa诱导的瘙痒性斑丘疹：病例报告和文献复习。

背景：红细胞生成刺激剂（ESA）是临床上常用的改善贫血的药物。尽管许多患者在没有不良事件的情况下成功接受了治疗，但其并发症此前已有报道。目的：报告和回顾ESA超敏反应的特点和管理。方法：1999年1月至2018年12月发表的与ESA使用相关的病例报告和相关文章，通过电子数据库（MEDLINE®和PubMed®）检索。对ESA的致命超敏反应和ESA的过敏交叉反应已有文献记载。EPO分子结构的脱敏或改变已被报道为重新引入该药物的成功方法。结论：ESA超敏反应在各种过敏反应和交叉反应中均有记载。脱敏和Epoetin结构改变可能是重新引入该药物的成功方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Asian Pacific journal of allergy and immunology 医学-过敏

CiteScore

12.80

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： The Asian Pacific Journal of Allergy and Immunology (APJAI) is an online open access journal with the recent impact factor (2018) 1.747 APJAI published 4 times per annum (March, June, September, December). Four issues constitute one volume. APJAI publishes original research articles of basic science, clinical science and reviews on various aspects of allergy and immunology. This journal is an official journal of and published by the Allergy, Asthma and Immunology Association, Thailand. The scopes include mechanism, pathogenesis, host-pathogen interaction, host-environment interaction, allergic diseases, immune-mediated diseases, epidemiology, diagnosis, treatment and prevention, immunotherapy, and vaccine. All papers are published in English and are refereed to international standards.